Drug Profile
Denfivontinib - Genosco
Alternative Names: G-801; SKI-G-801Latest Information Update: 18 Apr 2022
Price :
$50
*
At a glance
- Originator Genosco
- Developer Oscotec
- Class Antineoplastics; Small molecules
- Mechanism of Action Axl receptor tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Solid tumours
Most Recent Events
- 18 Apr 2022 SKI G 801 is still in phase I trials for Acute myeloid leukaemia in USA (Genosco pipeline, April 2022)
- 28 Jun 2021 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in USA (IV, Infusion)
- 10 Apr 2021 Oscotec plans a clinical trial in Non-small cell lung cancer (Combination therapy, First-line therapy)